Metabolic & Weight Loss — Category Comparisons
Published · Researched 2026-09-21
Research completed 2026-09-21 · 14 items · 58 verified real images · All prices observed 2026-09-20 unless otherwise noted.
Item roster (with validation tier and image count)
| # | Item | File | Tier | Images |
|---|---|---|---|---|
| 1 | Semaglutide | semaglutide | Tier 2 | 7/8 (missing: rear) |
| 2 | Tirzepatide | tirzepatide | Tier 2 | 6/8 (missing: rear, top) |
| 3 | Retatrutide | retatrutide | Tier 2 | 5/8 (missing: side, rear, top, owner-in-use) |
| 4 | Liraglutide | liraglutide | Tier 2 | 5/8 (missing: rear, detail, scale) |
| 5 | Orforglipron | orforglipron | Tier 2 | 7/8 (missing: rear) |
| 6 | AOD-9604 | aod-9604 | Tier 3 (weak) | 3/8 |
| 7 | Cagrilintide | cagrilintide | Tier 3 (weak) | 2/8 |
| 8 | CagriSema | cagrisema | Tier 3 (weak) | 0/8 (all labeled images are vendor CGI — rejected) |
| 9 | Pemvidutide | pemvidutide | Tier 3 (weak) | 0/8 (no real photos exist publicly) |
| 10 | SLU-PP-332 | slu-pp-332 | Tier 3 (weak) | 6/8 |
| 11 | MOTS-c | mots-c | Tier 3 (weak) | 6/8 (missing: owner-in-use, scale) |
| 12 | Humanin | humanin | Tier 3 (weak) | 1/8 |
| 13 | Pramlintide | pramlintide | UNVALIDATED | 5/8 |
| 14 | Survodutide | survodutide | UNVALIDATED | 5/8 |
Tier tally: Tier 2 = 5 · Tier 3 = 7 · UNVALIDATED = 2.
Substitutions (documented, none silent)
- SHLP-2 → SLU-PP-332. No meaningful social/community discussion was found for SHLP-2 anywhere; SLU-PP-332 had strong 2026 biohacking discussion (Threads creators, a dedicated Reddit subreddit, peptide forums). Total stayed at 14.
- Setmelanotide → Orforglipron. Setmelanotide failed the validation bar: Threads returned only 2 posts (a journal-article share and a 2023 link-drop, neither owner/user discussion), and Facebook found zero groups matching "setmelanotide". Orforglipron cleared the bar (multiple identifiable Threads discussion threads + presence across 6 GLP-1/peptide Facebook Groups). Honest flag: orforglipron is a small-molecule non-peptide, not a peptide — kept because it is what the community actually discusses, and flagged in the item file.
2026 factual corrections applied during research (pre-compilation)
- Orforglipron: the task brief described it as investigational. That was outdated — the FDA approved orforglipron as Foundayo™ on April 1, 2026 (CNPV program; verified via STAT News April 1, 2026 and LifeMD's April 10, 2026 GlobeNewswire release). The dossier reflects the approval reality.
- Humanin discovery: the brief credited the Pinchas Cohen lab; evidence shows Humanin was first reported by the Nishimoto lab (Hashimoto et al., PNAS 2001) — the Cohen lab built the metabolic framework later.
- Pemvidutide: Altimmune began enrolling the global PERFORMA Phase 3 MASH trial on August 3, 2026 (52-week readout anticipated 2029); "balanced 1:1" GLP-1/glucagon ratio confirmed by company materials. File updated.
- Survodutide: positive Phase 3 results announced June 7, 2026 — SYNCHRONIZE-1 up to 16.6% weight loss at 76 weeks vs 3.2% placebo; pre-specified substudy: up to 34% visceral-fat and 63.1% liver-fat reduction with lean-mass loss ≤10.8% of total tissue change; SYNCHRONIZE-MASLD met both primary endpoints (6 of 10 reached liver-fat normalization at 48 weeks). A conflicting 17.5%/"68 weeks" figure from one outlet was discarded as erroneous. File updated.
- Novo Nordisk pricing: Feb 24, 2026 press release cut US list to $675/mo across Ozempic/Wegovy/Rybelsus, effective January 1, 2027; NovoCare self-pay $149–$499/mo; TrumpRx portal $350/mo.
Specs head-to-head
| Item | Class | Approval status (Sept 2026) | Dosing | Key trial figure (sourced) |
|---|---|---|---|---|
| Semaglutide | GLP-1 RA | FDA/EMA-approved (Ozempic/Wegovy/Rybelsus) | Weekly injection (Ozempic/Wegovy); daily oral (Rybelsus) | STEP 1: −14.9% vs −2.4% (68 wks, NEJM 2021) |
| Tirzepatide | Dual GIP/GLP-1 | FDA/EMA-approved (Mounjaro/Zepbound) | Weekly injection | SURMOUNT-1: −20.9% at 15 mg vs −3.1% (72 wks, NEJM 2022) |
| Orforglipron | Oral small-molecule GLP-1 (non-peptide) | FDA-approved as Foundayo Apr 1, 2026; obesity/overweight only | Daily oral tablet, no food/water restrictions | ATTAIN-1: −12.4% at 36 mg capsule vs −0.9% (72 wks, NEJM Sept 2025) |
| Liraglutide | GLP-1 RA (first-gen) | FDA/EMA-approved (Victoza/Saxenda); Teva generic Saxenda launched Aug 2025 | Daily injection | SCALE: −8.4 kg vs −2.8 kg (56 wks, NEJM 2015) |
| Retatrutide | Triple GIP/GLP-1/GCGR agonist | Investigational (Phase 3 TRIUMPH) | Weekly injection | TRIUMPH-1 (announced May 21, 2026): −28.3% at 12 mg vs −2.2% (80 wks); 104-wk extension −30.3% |
| CagriSema | Amylin analog + GLP-1 combo | Investigational; FDA NDA filed Dec 2025, decision expected late 2026 | Weekly injection (16-wk titration) | REDEFINE-1: 20.4% ITT (22.7% on-treatment) at 68 wks; REDEFINE-4 (Feb 2026): 23.0% vs tirzepatide 25.5% — non-inferiority not met |
| Cagrilintide | Long-acting amylin analog | Investigational (mono) | Weekly injection (mono trials) | REDEFINE-1 cagrilintide-alone arm: 11.5% vs placebo 3.0% |
| Survodutide | Dual GCGR/GLP-1 | Investigational (Phase 3 SYNCHRONIZE) | Weekly injection | SYNCHRONIZE-1: 16.6% at 76 wks vs 3.2% (NEJM, June 2026) |
| Pemvidutide | Dual glucagon/GLP-1 (balanced 1:1) | Investigational (Phase 3 PERFORMA enrolling since Aug 3, 2026) | Weekly injection | MOMENTUM: 10.7% at 2.4 mg (24 wks); IMPACT: MASH resolution 59.1% vs 19.1% placebo (48 wks) |
| Pramlintide | Amylin analog | FDA-approved (Symlin, 2005) for T1D/T2D on mealtime insulin — not for weight loss | Mealtime injection, titratable | 6-mo trials: −1.4 to −1.6 kg vs +0.1 to +0.3 kg placebo; modest, adjunctive |
| AOD-9604 | hGH fragment 176-191 | Never approved; research chemical | Subcutaneous (gelling-prone reconstitution) | 24-wk Phase 2b (534 subjects): no meaningful separation from placebo — never peer-reviewed; efficacy disputed |
| SLU-PP-332 | ERRα agonist (oral) | Research chemical; no human trials | Oral capsules | Preclinical (mice) only: ~12% lower body weight, +70% treadmill endurance — no human data |
| MOTS-c | Mitochondrial-derived peptide (16-aa) | Research chemical; analog CB4211 reached Phase 1 (stalled) | Subcutaneous (short half-life) | CB4211 Phase 1a: safe, injection-site reactions; no human efficacy data for native MOTS-c |
| Humanin | Mitochondrial-derived peptide (24-aa) | Research chemical; no human trials | Subcutaneous | No human data of any kind; analogs preclinical only |
Value-for-money table (all dated; gray-market prices vendor-listed, not checkout-verified)
| Item | Cheapest legit path (2026-09-20) | Gray-market street anchor | Verdict |
|---|---|---|---|
| Semaglutide | TrumpRx $350/mo; NovoCare $149–$499/mo (self-pay); list $675/mo eff Jan 1, 2027 | Not observed — UNVERIFIED | Best-in-class value among approved brands if self-paying via TrumpRx/NovoCare |
| Tirzepatide | LillyDirect Zepbound self-pay: $299/mo (2.5 mg), $399/mo (5 mg), $449/mo (7.5–15 mg); Medicare not yet | Historical compounded $150–$300/mo (shortage era); no current verified price | Best efficacy-per-dollar approved option at LillyDirect self-pay tiers |
| Orforglipron | Foundayo WAC $649/mo; LillyDirect self-pay $149/$199/$299 tiers; $25 insured+savings card; Medicare $50 from Jul 2026 | Gray capsules 6 mg×90: $220–$239 | Convenience premium (daily pill, no restrictions); cheapest entry point of any brand GLP-1 |
| Liraglutide | GoodRx as low as $372.45/mo with coupon; compounded telehealth $198/$298/mo (Jul 2026, marketing copy) | Not observed separately | Cheapest approved-GLP-1 on-ramp via coupon; daily shot and weaker loss are the trade |
| Retatrutide | None — no legal pharmacy price | 10 mg: $69–$130 typical (US$99.99, AU$144.99–159.99, £60 sold out, €139.99); 30 mg: $170–$350 | Highest efficacy ceiling of the class, zero legal supply — the central paradox of the category |
| CagriSema | None (awaiting FDA decision late 2026) | Research blends $69–$240/vial or kit; guides cite $8–25/mg | No real product exists; every "CagriSema" image online is vendor CGI |
| Cagrilintide | None (not approved as mono) | $5.95–$37.43/mg after-code (e.g. 10 mg at $59.49–$150) | Cheap gray entry to amylin pharmacology, but the trial-grade effect belongs to the combo, not research powders |
| Survodutide | None — no legal pharmacy price | PGB 12 mg $225; Uther 10 mg $197; 5 mg $100 (Sept 2025, stale) | Premium-priced gray vials for an investigational drug with real Phase 3 body-composition data |
| Pemvidutide | None — no legal pharmacy price | None observed — UNVERIFIED | No market at all; pure pipeline-watch item |
| Pramlintide | SymlinPen 120: $1,209.52 / 5.4 mL (Drugs.com, 2026-09-20; possibly stale) | Not observed — UNVERIFIED | Expensive brand pen for a diabetes drug with modest weight effects; not a value play |
| AOD-9604 | None (never approved) | $49.99 / 5 mg vial (Amino Club w/ code, Jul 2026) | Cheapest peptide in the category — and the most-efficacy-disputed |
| SLU-PP-332 | None (research chemical) | Oral consumer range $56–$220/bottle | Priced like a supplement, evidenced like a hypothesis |
| MOTS-c | None (research chemical) | $40–$60 / 10 mg vial typical; ~$60–$180/mo community cycle | Inexpensive for a genuinely interesting mechanism — with zero human efficacy data |
| Humanin | None (research chemical) | 10 mg: $77–$191; 5 mg: $48.40–$295 | Paying real money for the least-evidenced item in the category |
Social-sentiment matrix
| Item | Tier | Platform pulse | Praise themes | Complaint themes |
|---|---|---|---|---|
| Semaglutide | 2 | FB Groups (live: "GLP1 Weight Loss Journey", "GLP-1 Care & Conversation"), Threads physicians | The benchmark; appetite control, insurance-independent wins via TrumpRx | GI sides, Ozempic face, hair thinning, insurance/PAs, weight regain off-drug (STEP 4: ~2/3 regained in a year) |
| Tirzepatide | 2 | FB Groups strongest ("Zepbound support and success" ~1,000; "Zepbound Meals And Motivation"); Threads sparse | Stronger loss than sema; LillyDirect price tiers applauded; maintenance journeys | Fear of long-term effects (countered by @louisjohnsonpt); sourcing confusion post-shortage |
| Orforglipron | 2 | Threads dominant (ATTAIN explainers, physician bioavailability debates, post-launch ad fatigue); FB Groups present-but-weak | Daily pill, no food/water rules — removes the needle and the Rybelsus timing burden | "Good enough?" vs injectables; brand ad-fatigue ("STOP SHOWING ME MOUNJARO AND FOUNDAYO") |
| Liraglutide | 2 | FB Groups ("Victoza journey" — fresh Sept 2026 posts), Threads verified physicians | Affordable workhorse; still initiated today; coverage-friendly | Daily shot; weaker loss; fatigue/sleep/menstrual-cycle reports; compounding-clinic marketing noise |
| Retatrutide | 2 | FB Groups (dedicated Reta groups ~2–3k members, vendor-reputation clearinghouse behavior); Threads dense adverse-event threads | Most-hyped compound of 2026; −28% Phase 3 figure; 5-stone-loss ambassadors | Vendor mislabeling/low-purity vials blamed for non-response; the Giles Yeo question: "how do we even know it's retatrutide?" |
| AOD-9604 | 3 | Threads + TikTok (@barrythebiooptimizer: "most frustrating fat loss peptide?") | Stubborn-fat reports over 8–12 wks; no appetite suppression; tolerable | 30–50% get zero results (responder genetics); reconstitution gelling "nightmare"; Phase 2b showed no separation from placebo |
| Cagrilintide | 3 | Threads only (trial-watch chatter, SE-Asia retail curiosity) | Amylin pathway excitement via REDEFINE data | Gray-market powders ≠ trial formulation; discussion is pipeline-focused, not experiential |
| CagriSema | 3 | Threads only (clinicians, REDEFINE-4 counter-narrative) | "Most anticipated combo" pre-readout | Two-act disappointment: missed ~25% whisper number, then REDEFINE-4 loss to tirzepatide (non-inferiority not met) |
| Pemvidutide | 3 | One glp1forum thread (group-buy organizing, Dec 2024); Threads pipeline mentions | Liver-fat angle (MASH) distinct from pure weight-loss drugs | Skepticism dominant; weak A1c; Altimmune stock mockery |
| SLU-PP-332 | 3 | Threads creators + Reddit r/SLUPP332 + forums; no FB Groups signal | Energy/euphoria, thermogenesis, gym sweat; oral convenience | No human trials — all preclinical; dosing chaos (250 mcg–100 mg); substitute images for rear/top |
| MOTS-c | 3 | Threads (sparse); adjacent TikTok/YouTube explainers; rapamycin.news | "Exercise mimetic" mechanism; energy/endurance adjunct | Oral products "almost certainly wasted money"; thin footprint; stalled CB4211 program |
| Humanin | 3 | Threads only (a verified practitioner + one skeptic) | Longevity/neuroprotection framing in deep-biohacker stacks | Lives in MOTS-c's shadow; no owner community; native-vs-analog label chaos |
| Pramlintide | UNV | Forums/review sites (WebMD, diabetes.co.uk, TuDiabetes) — no Meta-platform pulse | Respected amylin elder; insulin-sparing; weight maintenance context | Mealtime injections; early nausea; hypoglycemia risk with insulin — keeps it a clinic drug |
| Survodutide | UNV | Peptide forums (glp1forum, MESO-Rx, professionamuscle) — no Meta-platform pulse | Real Phase 3 body-composition data (34% visceral, 63.1% liver fat) | Gray-market-only access; heart-rate anecdote; vendor-sourcing grind |
Use-case fit and risk matrix
| Use case | Best fits | Worst fits |
|---|---|---|
| Maximum proven weight loss, insured | Tirzepatide (SURMOUNT −20.9%); Semaglutide (STEP −14.9%) | AOD-9604 (disputed efficacy); SLU-PP-332 (no human data) |
| Needle-free, lowest friction | Orforglipron/Foundayo (daily pill, no food/water rules) | Pramlintide (mealtime injections); Liraglutide (daily shot) |
| Tightest budget, approved drug | Liraglutide (GoodRx ~$372/mo coupon); Tirzepatide via LillyDirect $299/mo starter | Pramlintide (SymlinPen $1,209.52 — diabetes drug, modest loss) |
| Fat loss with liver-fat targeting (MASH angle) | Survodutide (63.1% liver-fat reduction, Phase 3); Pemvidutide (MASH resolution 59.1%, Phase 3 enrolling) | SLU-PP-332, Humanin (no liver data at all) |
| Body-recomposition / biohacking adjunct | MOTS-c (exercise-mimetic mechanism); SLU-PP-332 (ERRα, preclinical) | Orforglipron (convenience, not an adjunct); Pramlintide (clinic drug) |
| Highest risk-adjusted danger | — | Retatrutide (unverifiable vials, no legal supply); AOD-9604 (gelling + responder lottery); any gray-market vial (identity/purity/sterility unregulated — the FDA's April 2026 safety communication explicitly warned about compounded/unapproved GLP-1 products) |
Headline takeaways
- 2026 is the year weight-loss drugs left the syringe behind. Two oral options are now FDA-approved (Rybelsus/ Wegovy-pill from late 2025; Foundayo April 2026) — and the community's clearest verdict is that Foundayo's any-time-of-day dosing beats Rybelsus's empty-stomach ritual.
- Retatrutide is the paradox of the category: the most-discussed compound in 2026 gray-market culture with the strongest Phase 3 numbers (−28.3%) — and zero legal supply. The community's own defining question is whether any given vial actually contains labeled retatrutide.
- The amylin chapter is CagriSema's to lose — and it's wobbling. REDEFINE-4's head-to-head loss to tirzepatide (non-inferiority not met) deflated the "most anticipated combo" narrative; cagrilintide gray-market powders have nothing to do with the trial formulation.
- Liver-fat drugs are the sleeper layer. Survodutide's 63.1% liver-fat reduction and pemvidutide's active Phase 3 MASH program (PERFORMA, enrolling since Aug 2026) reframe weight-loss peptides as metabolic-disease drugs — the forum communities haven't caught up to the data.
- The mitochondrial niche (MOTS-c, Humanin, SLU-PP-332) runs on mechanisms, not evidence. Genuinely interesting science, near-zero human data, thin Meta-platform validation — Tier 3 across the board, two of them weak enough to flag.
- Price reality check: self-pay approved GLP-1s now start at $149–$350/mo (TrumpRx, LillyDirect, NovoCare) — close to or below gray-market vial economics once purity risk is priced in.
Social-pulse summary
- Platforms searched: Threads, Facebook (groups + posts + Marketplace), Instagram, plus secondary web/social layers for every item (16-item worker grid across the track, with a final single-item-worker pass).
- Facebook Groups remain the highest-signal layer for the mainstream GLP-1s: live Sept 2026 posts in Zepbound support groups (~1,000 members), Victoza journey (260), Tirzepatide groups (410–1,000), and dedicated Retatrutide groups (2,000–3,000). The large private Ozempic/Wegovy groups were out of tool reach — a known blind spot.
- Threads carried the pipeline-watch layer: ATTAIN/REDEFINE readouts, physician explainers, adverse-event megathreads (retatrutide @thecopticbrother thread: 127 likes, 248 replies), and post-launch Foundayo ad fatigue.
- Instagram owner content was the weakest leg across the track — the available CLI reads only the user's own account, and cross-platform social.search timed out repeatedly; IG signal is flagged weak/unassessed in most files rather than claimed.
- What drives each pick: semaglutide — ambient cultural dominance; tirzepatide — maintenance-journey groups; orforglipron — oral-convenience hype + ad fatigue; liraglutide — budget/coupon discourse; retatrutide — gray-market results culture; cagrisema/cagrilintide — trial-readout watching; survodutide/pemvidutide — forum-only gray pipeline interest; AOD-9604 — frustration-complaint virality; SLU-PP-332 — creator/biohacker stacks; MOTS-c/Humanin — longevity-crossover whispers; pramlintide — legacy forum knowledge base.
Report index
- semaglutide — Semaglutide (Novo Nordisk; Ozempic/Wegovy/Rybelsus)
- tirzepatide — Tirzepatide (Lilly; Mounjaro/Zepbound)
- retatrutide — Retatrutide (Lilly; investigational triple agonist)
- liraglutide — Liraglutide (Novo Nordisk; Victoza/Saxenda)
- orforglipron — Orforglipron (Lilly; Foundayo — FDA-approved Apr 1, 2026)
- aod-9604 — AOD-9604 (hGH fragment 176-191)
- cagrilintide — Cagrilintide (Novo Nordisk; amylin analog)
- cagrisema — CagriSema (Novo Nordisk; investigational combo)
- pemvidutide — Pemvidutide (Altimmune; PERFORMA Phase 3 enrolling)
- slu-pp-332 — SLU-PP-332 (ERRα agonist; research chemical)
- mots-c — MOTS-c (mitochondrial-derived peptide)
- humanin — Humanin (mitochondrial-derived peptide)
- pramlintide — Pramlintide (AstraZeneca; Symlin/SymlinPen)
- survodutide — Survodutide (Boehringer Ingelheim / Zealand Pharma; investigational)
Images: img/ — 58 verified real JPEGs (zero synthetic). Each dossier notes which photo views were captured.
UNVERIFIED aggregate (category-level watch list)
- Gray-market vial identity — for retatrutide, survodutide, cagrisema, cagrilintide, AOD-9604, SLU-PP-332, MOTS-c, and Humanin, no purchased vial's contents were independently lab-verified; all vendor purity/COA claims are marketing until tested.
- Compounding-enforcement status — post-shortage compounding wind-downs and the FDA's 2026 warning letters are community-reported; docket-level confirmation not re-pulled.
- Compounded street prices — current compounded semaglutide/liraglutide pricing figures are stale or marketing copy; no 2026-dated checkout confirmations.
- Generic liraglutide retail pricing — Teva generic Saxenda launched Aug 28, 2025; no published retail price observed.
- Instagram owner-content presence — unassessed for most items (tool limitation), flagged per file rather than assumed absent.
- Marketplace used ranges — none observed for any item (prescription injectables have no legal used channel; research chemicals showed zero listings).
- Oral-bioavailability claims — vendor claims for oral MOTS-c and the SLU-PP-332 dose chaos (250 mcg–100 mg) are unverified; orforglipron's true oral bioavailability is debated (77% claim vs published 30–40%).
Caveats
- Large private Facebook Ozempic/Wegovy groups were out of tool reach; their absence skews semaglutide's group-size picture downward.
- Image coverage is honest, not full: CagriSema (0/8) and Pemvidutide (0/8) have no real photographs in existence; Humanin (1/8) has one vendor photo; substitute views are labeled as substitutes, never as real angles.
- Trial figures are drawn from press releases and journal publications cited on the dossier pages; gray-market dosing protocols are community-reported and are not medical guidance.
- Sponsored content flagged in-file: a vendor Threads account's trial-trajectory posts (retatrutide), a sponsored wellness-clinic PR (MOTS-c), and ad-adjacent nutrition promos in Facebook groups.
Not medical advice. This is research material only; consult a qualified clinician.
Named sources
- Threads @louisjohnsonpt — | Tirzepatide | 2 | FB Groups strongest ("Zepbound support and success" ~1,000; "Zepbound Meals And Motivation"); Threads sparse | Stronger loss than sema; LillyDirect price tiers applauded; maintenance journeys | Fear of long-term effects (countered by @louisjohnsonpt); sourcing confusion…
- TikTok @barrythebiooptimizer — | AOD-9604 | 3 | Threads + TikTok (@barrythebiooptimizer: "most frustrating fat loss peptide?") | Stubborn-fat reports over 8–12 wks; no appetite suppression; tolerable | 30–50% get zero results (responder genetics); reconstitution gelling "nightmare"; Phase 2b showed no separation from placebo |
- Threads @thecopticbrother — adverse-event megathreads (retatrutide @thecopticbrother thread: 127 likes, 248 replies)
- Facebook group: Victoza journey — 260
- Tirzepatide groups — 410–1,000
- Retatrutide groups — 2,000–3,000
- Threads group: ATTAIN/REDEFINE readouts, physician explainers, adverse-event megathreads — retatrutide @thecopticbrother thread: 127 likes, 248 replies
Source URLs were not recorded for these references.